544 related articles for article (PubMed ID: 33705753)
1. MYC-Mediated Ribosomal Gene Expression Sensitizes Enzalutamide-resistant Prostate Cancer Cells to EP300/CREBBP Inhibitors.
Furlan T; Kirchmair A; Sampson N; Puhr M; Gruber M; Trajanoski Z; Santer FR; Parson W; Handle F; Culig Z
Am J Pathol; 2021 Jun; 191(6):1094-1107. PubMed ID: 33705753
[TBL] [Abstract][Full Text] [Related]
2. CREBBP/EP300 bromodomains are critical to sustain the GATA1/MYC regulatory axis in proliferation.
Garcia-Carpizo V; Ruiz-Llorente S; Sarmentero J; Graña-Castro O; Pisano DG; Barrero MJ
Epigenetics Chromatin; 2018 Jun; 11(1):30. PubMed ID: 29884215
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological and genetic targeting of 5-lipoxygenase interrupts c-Myc oncogenic signaling and kills enzalutamide-resistant prostate cancer cells via apoptosis.
Monga J; Subramani D; Bharathan A; Ghosh J
Sci Rep; 2020 Apr; 10(1):6649. PubMed ID: 32313135
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of the erythropoietin-producing receptor EPHB4 antagonizes androgen receptor overexpression and reduces enzalutamide resistance.
Li C; Lanman NA; Kong Y; He D; Mao F; Farah E; Zhang Y; Liu J; Wang C; Wei Q; Liu X
J Biol Chem; 2020 Apr; 295(16):5470-5483. PubMed ID: 32184358
[TBL] [Abstract][Full Text] [Related]
5. Role of solute carrier transporters SLC25A17 and SLC27A6 in acquired resistance to enzalutamide in castration-resistant prostate cancer.
Kushwaha PP; Verma SS; Shankar E; Lin S; Gupta S
Mol Carcinog; 2022 Apr; 61(4):397-407. PubMed ID: 34939235
[TBL] [Abstract][Full Text] [Related]
6. CREBBP/EP300 Bromodomain Inhibition Affects the Proliferation of AR-Positive Breast Cancer Cell Lines.
Garcia-Carpizo V; Ruiz-Llorente S; Sarmentero J; González-Corpas A; Barrero MJ
Mol Cancer Res; 2019 Mar; 17(3):720-730. PubMed ID: 30606771
[TBL] [Abstract][Full Text] [Related]
7. Aspalathus linearis suppresses cell survival and proliferation of enzalutamide-resistant prostate cancer cells via inhibition of c-Myc and stability of androgen receptor.
Wang BJ; Huang SH; Kao CL; Muller CJF; Wang YP; Chang KH; Wen HC; Yeh CC; Shih LJ; Kao YH; Huang SP; Li CY; Chuu CP
PLoS One; 2022; 17(7):e0270803. PubMed ID: 35776912
[TBL] [Abstract][Full Text] [Related]
8. Metabolic Reprogramming and Predominance of Solute Carrier Genes during Acquired Enzalutamide Resistance in Prostate Cancer.
Verma S; Shankar E; Chan ER; Gupta S
Cells; 2020 Nov; 9(12):. PubMed ID: 33255236
[TBL] [Abstract][Full Text] [Related]
9. Niclosamide inhibits androgen receptor variants expression and overcomes enzalutamide resistance in castration-resistant prostate cancer.
Liu C; Lou W; Zhu Y; Nadiminty N; Schwartz CT; Evans CP; Gao AC
Clin Cancer Res; 2014 Jun; 20(12):3198-3210. PubMed ID: 24740322
[TBL] [Abstract][Full Text] [Related]
10. Targeting the KDM4B-AR-c-Myc axis promotes sensitivity to androgen receptor-targeted therapy in advanced prostate cancer.
Tang DE; Dai Y; He JX; Lin LW; Leng QX; Geng XY; Fu DX; Jiang HW; Xu SH
J Pathol; 2020 Oct; 252(2):101-113. PubMed ID: 32617978
[TBL] [Abstract][Full Text] [Related]
11. Mechanisms of enzalutamide resistance in castration-resistant prostate cancer and therapeutic strategies to overcome it.
Wang Y; Chen J; Wu Z; Ding W; Gao S; Gao Y; Xu C
Br J Pharmacol; 2021 Jan; 178(2):239-261. PubMed ID: 33150960
[TBL] [Abstract][Full Text] [Related]
12. Effect of Monoamine oxidase A (MAOA) inhibitors on androgen-sensitive and castration-resistant prostate cancer cells.
Gaur S; Gross ME; Liao CP; Qian B; Shih JC
Prostate; 2019 May; 79(6):667-677. PubMed ID: 30693539
[TBL] [Abstract][Full Text] [Related]
13. Y08197 is a novel and selective CBP/EP300 bromodomain inhibitor for the treatment of prostate cancer.
Zou LJ; Xiang QP; Xue XQ; Zhang C; Li CC; Wang C; Li Q; Wang R; Wu S; Zhou YL; Zhang Y; Xu Y
Acta Pharmacol Sin; 2019 Nov; 40(11):1436-1447. PubMed ID: 31097763
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of enhancer of zeste homolog 2 (EZH2) overcomes enzalutamide resistance in castration-resistant prostate cancer.
Bai Y; Zhang Z; Cheng L; Wang R; Chen X; Kong Y; Feng F; Ahmad N; Li L; Liu X
J Biol Chem; 2019 Jun; 294(25):9911-9923. PubMed ID: 31085587
[TBL] [Abstract][Full Text] [Related]
15. ISL1 promotes enzalutamide resistance in castration-resistant prostate cancer (CRPC) through epithelial to mesenchymal transition (EMT).
Choi JD; Kim TJ; Jeong BC; Jeon HG; Jeon SS; Kang MY; Yeom SY; Seo SI
Sci Rep; 2021 Nov; 11(1):21984. PubMed ID: 34753990
[TBL] [Abstract][Full Text] [Related]
16. Upregulation of ATP Binding Cassette Subfamily C Member 5 facilitates Prostate Cancer progression and Enzalutamide resistance via the CDK1-mediated AR Ser81 Phosphorylation Pathway.
Ji G; He S; Huang C; Gong Y; Li X; Zhou L
Int J Biol Sci; 2021; 17(7):1613-1628. PubMed ID: 33994848
[TBL] [Abstract][Full Text] [Related]
17. Steroid Sulfatase Stimulates Intracrine Androgen Synthesis and is a Therapeutic Target for Advanced Prostate Cancer.
Armstrong CM; Liu C; Liu L; Yang JC; Lou W; Zhao R; Ning S; Lombard AP; Zhao J; D'Abronzo LS; Evans CP; Li PK; Gao AC
Clin Cancer Res; 2020 Nov; 26(22):6064-6074. PubMed ID: 32928794
[TBL] [Abstract][Full Text] [Related]
18. Targeting CPT1B as a potential therapeutic strategy in castration-resistant and enzalutamide-resistant prostate cancer.
Abudurexiti M; Zhu W; Wang Y; Wang J; Xu W; Huang Y; Zhu Y; Shi G; Zhang H; Zhu Y; Shen Y; Dai B; Wan F; Lin G; Ye D
Prostate; 2020 Sep; 80(12):950-961. PubMed ID: 32648618
[TBL] [Abstract][Full Text] [Related]
19. Preclinical Study using Malat1 Small Interfering RNA or Androgen Receptor Splicing Variant 7 Degradation Enhancer ASC-J9
Wang R; Sun Y; Li L; Niu Y; Lin W; Lin C; Antonarakis ES; Luo J; Yeh S; Chang C
Eur Urol; 2017 Nov; 72(5):835-844. PubMed ID: 28528814
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of cholesterol biosynthesis overcomes enzalutamide resistance in castration-resistant prostate cancer (CRPC).
Kong Y; Cheng L; Mao F; Zhang Z; Zhang Y; Farah E; Bosler J; Bai Y; Ahmad N; Kuang S; Li L; Liu X
J Biol Chem; 2018 Sep; 293(37):14328-14341. PubMed ID: 30089652
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
